Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy
Choueiri T, Regan M, Rosenberg J, Oh W, Clement J, Amato A, McDermott D, Cho D, Atkins M, Signoretti S. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy. BJU International 2010, 106: 772-778. PMID: 20230385, DOI: 10.1111/j.1464-410x.2010.09218.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntigens, NeoplasmAntineoplastic AgentsBenzenesulfonatesCarbonic Anhydrase IXCarbonic AnhydrasesCarcinoma, Renal CellEpidemiologic MethodsFemaleHumansImmunohistochemistryIndolesKidney NeoplasmsMaleMiddle AgedNeoplasm ProteinsNiacinamidePhenylurea CompoundsPrognosisPyridinesPyrrolesSorafenibSunitinibTreatment OutcomeVascular Endothelial Growth Factor AConceptsMetastatic clear-cell renal cell carcinomaVEGF-targeted therapyCarbonic anhydrase IXClear-cell renal cell carcinomaClear-cell componentRenal cell carcinomaTumor shrinkageCell carcinomaClear-cellTreated with vascular endothelial growth factor (VEGF)-targeted therapyVascular endothelial growth factor (VEGF)-targeted therapyVascular endothelial growth factor-targeted therapyAssociated with greater tumor shrinkageCarbonic anhydrase IX expressionResponse to sorafenib treatmentSunitinib-treated patientsResponse to sunitinibSorafenib-treated patientsPredictors of outcomeSunitinib treatmentSorafenib treatmentPrimary endpointPredictive biomarkersPrognostic valueCAIX expression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply